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Introduction
Myocardial infarction commonly results from athero-
sclerosis of the coronary arteries. For relatively young
patients, myocardial infarction is associated with un-
conventional risk factors such as hyperhomocysteine-
mia.1,2 Acute myeloid leukemia (AML) may predispose
patients to hypercoagulable states such as dissemi-
nated intravascular coagulation or hyperleukocyto-
sis.3,4 The association of acute myocardial infarction
(AMI) and AML is rare and the pathogenic relation-
ship between these entities undefined. We herein report
the case of a patient with concurrence of AML and
AMI. We propose that leukemia-related hyperhomo-
cysteinemia may have a pathogenic role in the devel-
opment of thrombosis.
Case Report
In June 2006, a 40-year-old female had epigastric pain
with radiation to the chest and left axillary areas. It was
accompanied by vomiting and cold sweating. She did
not smoke and had neither family history of coronary
artery disease nor past history of diabetes mellitus,
hypertension or hyperlipidemia. She visited a local
hospital. The initial electrocardiography (ECG) and
echocardiography showed normal results, but the
hemogram revealed leukocytosis with blasts.
She was referred to our hospital. ECG revealed
pathological Q-wave and ST elevation in leads II, III
and AVF (Figure 1). The physical examination was
unremarkable. The initial biochemical study revealed
creatine kinase-MB of 51.9ng/mL (normal, <10.4ng/
mL) and troponin-I of 30.64 ng/mL (normal,
< 0.16 ng/mL). The patient was admitted to the
coronary care unit. Hemogram showed hemoglobin
of 11.6 g/dL, platelet count of 122,000/mm3 and
white blood cell count of 11,000/mm3 with 83%
blasts, 2% promyelocytes, 1% metamyelocytes, 6%
neutrophils, 7% lymphocytes and 1% eosinophils.
Serum creatinine was 0.7 mg/dL and cholesterol was
199mg/dL. Her homocysteine level was 13.7µmol/L.
Protein C, protein S and antithrombin III activities
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were 100.7%, 102% and 110%, respectively. Coagula-
tion profile showed prothrombin time of 13.4 seconds
(control, 10.8 seconds; international normalized ratio
[INR], 1.22), activated partial thromboplastin time
of 33.1 seconds (control, 28.4 seconds), fibrinogen
of 411 mg/dL, and D-dimer of 7,002.79 ng/mL.
Lupus anticoagulant was negative. The patient received
medical treatment with aspirin, clopidogrel, nitrate,
propranolol and enoxaparin 60 mg subcutaneous injec-
tion per day. The diagnosis of AML, M1, was estab-
lished by a bone marrow aspiration smear (Figure 2).
The karyotype was 46,XY. Flow cytometry showed
that the leukemic cells were positive for CD33, CD13
and CD117, and negative for CD7 and CD19.
On the 12th day after the onset of chest pain, the
patient received chemotherapy with cytarabine 100mg/
m2 continuous intravenous infusion for 7 days and
etoposide 100 mg/m2 intravenous drip 3 hours for 
3 days. She had sudden blurred vision on the 14th day
after the initiation of chemotherapy and the 26th day
after the onset of chest pain. The ophthalmologist was
consulted. Bilateral retinal hemorrhage was observed.
Sinus thrombosis was suspected and cerebral magnetic
resonance imaging confirmed the diagnosis of right
lateral dural sinus thrombosis (Figure 3). Hemogram
at that time showed hemoglobin 8.4 g/dL, platelets
35,000/mm3 and white blood cells 900/mm3. We
gave enoxaparin 60 mg/day subcutaneous injection,
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Figure 1. Electrocardiography shows pathological Q-wave and ST elevation in leads II, III and AVF.
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Figure 2. (A) Bone marrow and (B) peripheral blood smears show many blast cells.
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followed by warfarin 5 mg/day, adjusted to keep the
INR of prothrombin time within 2–3 times the normal
range. The patient’s visual acuity gradually improved.
Subsequent bone marrow aspiration smear confirmed
that she had complete remission.
During the period of remission, her homocysteine
level fell to 10.9 µmol/L after folic acid supplementa-
tion for 2 months, after which she stopped taking folic
acid. Another 6 weeks later, her homocysteine level
fell to 9.8µmol/L. She completed post-remission treat-
ment with 6 cycles of high-dose cytarabine. No further
chest pain or visual disturbance was noted.
Discussion
The association of AML and AMI is rare, and the re-
lationship between these 2 entities is undefined.5 For
acute promyelocytic leukemia (AML, M3), AMI may
result from a hypercoagulable state caused by dissem-
inated intravascular coagulation.3 Patients with AML,
other than M3, who present with a hypercoagulable
state are few in number, and its association with AMI
is rare. We reviewed the English-language literature and
found no more than 4 cases.4–7 The clinical features
of these cases and our own are summarized in Table 1.
Compared with the average age of AMI patients, these
cases are relatively young. One of them had smoking
history5 and another had a positive family history of
coronary artery disease.6 The risk factors for myocar-
dial infarction appeared less prominent than generally
considered. The hypercoagulable states have never been
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Figure 3. Brain magnetic resonance imaging shows thrombosis
of the right lateral dural sinus (arrows).
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described in detail. One of them had hyperleukocyto-
sis, which was considered to be the major contributor
to infarction.4 The homocysteine level was normal in 1
case,6 elevated in our case, and not mentioned in the
remaining cases. As for the treatment of AML, com-
plete remission was successfully induced in 3 cases,
while blasts could still be found in the peripheral blood
of the earliest case.7 The treatment result was not
available in 1 case.5 Anthracycline was avoided due to
concern regarding its potential cardiotoxicity in all 4
cases whose treatment regimens were described.4,6,7
In our case, we replaced anthracycline with etoposide.
The induction therapy was also successful. Although
there is only limited experience, avoiding anthracycline
appears to be safe and equally effective in remission
induction.
Several mechanisms are proposed for myocardial
infarction in patients with AML, including leukemic
infiltration into the myocardium,5 effects of the an-
tileukemic chemotherapy, especially anthracycline,5
occlusion of coronary arteries by leukemic throm-
bus,5,6 hemorrhage in the myocardium or intima of a
coronary artery,5 leukostasis syndrome,4,5 disseminated
intravascular coagulation,5 and deficiency of coagula-
tion factors.5,8 Jachmann-Jahn et al suggested leukemic
thrombus as the etiology.6 Cohen et al considered
AMI as part of leukostasis syndrome as their patient
had extreme leukocytosis.4 Deficiency of protein C,
protein S and antithrombin III has been demon-
strated,8 but whether such deficiencies lead to AMI is
still not clear.
In our case, the white blood cell count at presen-
tation was 11,000/mm3, which made leukostasis less
likely. The unique feature of our case is the subsequent
dural sinus thrombosis, which developed during treat-
ment of AML. The white blood cell count was 900/
mm3, indicating further that leukostasis was unlikely
to have been the cause of thrombosis. In the presence
of indwelling catheter, catheter-related thrombosis 
is another consideration. However, the majority of
catheter-related thromboses developed in the upper
extremities,9 and the myocardial infarction in our case
actually occurred before catheter implantation. On
the other hand, our patient had hyperhomocysteine-
mia, which is a risk factor for both arterial and venous
thromboembolism.10–12 The risk of AMI is increased
2-fold when homocysteine level is > 10.2 µmol/L and
9-fold when it is > 20 µmol/L.11 Homocysteine was
found to be frequently elevated in rapidly proliferative
tumors even though they were not treated with anti-
folate drugs.13 It was also proposed that homocysteine
could serve as a potential tumor marker.13 The levels
of homocysteine in leukemic patients have not been
studied extensively. In our case, homocysteine level
was increased on diagnosis but declined after chemo-
therapy and folic acid supplement. Although direct
evidence of hyperhomocysteinemia resulting from leu-
kemia is weak, our patient’s homocysteine level was
normal after cessation of folic acid during the remission
phase of her leukemia. This suggests that her hyper-
homocysteinemia was related to leukemia rather than
to genetic defects in homocysteine metabolism.
Our report is limited in several aspects. Homocys-
teine level may vary with the menstrual cycle in young
females,14 and the levels measured in our spot samples
may be affected. The causal relationship between hyper-
homocysteinemia and AMI or dural sinus thrombosis
cannot be established with such limited evidence. Con-
sidering that she did not have any risk factor for coro-
nary artery disease and that the other screening tests
for thrombophilia, including protein C, protein S, an-
tithrombin III and lupus anticoagulant, were normal,
we suggest that the patient’s AMI and sinus throm-
bosis stemmed from leukemia per se or the resultant
hyperhomocysteinemia.
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